Xenon Pharmaceuticals Inc. (XENE)
| Market Cap | 3.62B +10.5% |
| Revenue (ttm) | n/a |
| Net Income | -409.20M |
| EPS | -4.73 |
| Shares Out | 96.84M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,112,366 |
| Open | 37.54 |
| Previous Close | 37.54 |
| Day's Range | 36.84 - 38.12 |
| 52-Week Range | 33.38 - 72.66 |
| Beta | 0.08 |
| Analysts | Strong Buy |
| Price Target | 71.94 (+92.3%) |
| Est. Earnings | Nov 13, 2026 |
About XENE
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In a... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for XENE stock is "Strong Buy." The 12-month stock price target is $71.94, which is an increase of 92.30% from the latest price.
News
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, BC and BOSTON, MA, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical develo...
Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain
XEN1701 achieved target profile, including desired Na V 1.7 receptor occupancy in both the peripheral and central nervous system, and was generally well-tolerated with no notable autonomic cardiovascu...
Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors
NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is continuing its investigation into potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. (“Xenon”) common stock (NASDAQ: ...
Xenon Pharmaceuticals assumed with a Buy at Guggenheim
Guggenheim assumed coverage of Xenon Pharmaceuticals (XENE), which was previously covered by Yatin Suneja, with a Buy rating and $73 price target The firm’s ivnestment case rests on an epilepsy…
Xenon Pharmaceuticals CFO buys 15,000 shares
Xenon Pharmaceuticals (XENE) CFO Thomas Kelly purchased 15,000 shares at an average price of $37.32 for a value of $559,740, as reported in a regulatory filing.
Xenon Pharmaceuticals CEO buys 30,000 shares
Xenon Pharmaceuticals (XENE) CEO Ian Mortimer purchased 30,000 shares at an average price $37.38 for a value of $1,121,400, as reported in a regulatory filing.
Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors
Montreal, Quebec--(Newsfile Corp. - September 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company developi...
Xenon Pharmaceuticals Transcript: TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
Azetukalner's NDA for focal-onset seizures was filed after strong efficacy and safety results, with commercial launch preparations underway and four dose strengths planned. The phase III psychiatry program is paused for dose optimization, with key MDD data expected in Q1 2027. Early-stage pain programs are advancing to phase II.
XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $XENE--XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law.
Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE)
Analysts cut price targets and reduced their estimates for azetukalner's psychiatric commercial opportunity after Xenon Pharmaceuticals disclosed an enrollment pause in its Phase 3 depression trials -...
Wolf Popper LLP Announces Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. (“Xenon”) common stock (NASDAQ: XENE).
Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
VANCOUVER, BC and BOSTON, MA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical devel...
Xenon Pharmaceuticals falls -28.9%
Xenon Pharmaceuticals (XENE) is down -28.9%, or -$16.60 to $40.75.
Xenon Pharmaceuticals falls -29.8%
Xenon Pharmaceuticals (XENE) is down -29.8%, or -$17.08 to $40.27.
Xenon Pharmaceuticals price target lowered to $70 from $81 at RBC Capital
RBC Capital lowered the firm’s price target on Xenon Pharmaceuticals (XENE) to $70 from $81 and keeps an Outperform rating on the shares. The firm cites the company having paused…
Xenon Pharmaceuticals price target lowered to $55 from $71 at Wedbush
Wedbush lowered the firm’s price target on Xenon Pharmaceuticals (XENE) to $55 from $71 and keeps an Outperform rating on the shares. The firm notes the company Xenon disclosed a…
Xenon Stock Faces Worst Day Since 2017 as Lead Drug Proves a Double-Edged Sword
Xenon Pharmaceuticals says it paused trials for azetukalner in major depressive disorder and bipolar depression following ‘adverse events.'
Xenon Pharmaceuticals price target lowered to $60 from $78 at Needham
Needham lowered the firm’s price target on Xenon Pharmaceuticals (XENE) to $60 from $78 and keeps a Buy rating on the shares. The firm cites the company having paused the…
Xenon Pharmaceuticals price target lowered to $90 from $97 at Baird
Baird lowered the firm’s price target on Xenon Pharmaceuticals (XENE) to $90 from $97 and keeps an Outperform rating on the shares.
Xenon Pharmaceuticals price target lowered to $64 from $69 at Wells Fargo
Wells Fargo analyst Benjamin Burnett lowered the firm’s price target on Xenon Pharmaceuticals (XENE) to $64 from $69 and keeps an Overweight rating on the shares. The firm notes shares…
Citi views Xenon study pause as positive for Biohaven
Citi analyst Samantha Semenkow views Xenon Pharmaceuticals’ (XENE) voluntarily pause in new enrollment for its ongoing trials for major depressive disorder and bipolar depression as favorable for Bioh...
Xenon Pharmaceuticals downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst David Hoang downgraded Xenon Pharmaceuticals (XENE) to Hold from Buy with a price target of $46, down from $90. The company reported neuropsychiatric adverse events in its…
Xenon pauses new enrollment in depression, bipolar disorder trials over side-effect concerns
Xenon Pharmaceuticals on Thursday said it has temporarily paused enrolling new patients in clinical studies testing its experimental drug for major depression and bipolar disorder, following reports...
Xenon Pharmaceuticals Transcript: FDA announcement
Azetukalner's focal-seizure NDA was submitted to the FDA, while MDD and bipolar-depression enrollment was temporarily paused for tolerability-focused changes. X-NOVA2 results are expected in Q1 2027.
Xenon Pharmaceuticals Press release: FDA announcement
Xenon Pharmaceuticals issued a press release on September 17, 2026, disclosing material business information to investors.